» Articles » PMID: 3040415

Relationship Between Tumour Size and Uptake of Radiolabelled Anti-CEA in a Colon Tumour Xenograft

Overview
Journal Eur J Nucl Med
Specialty Nuclear Medicine
Date 1987 Jan 1
PMID 3040415
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The relationship between tumour size and the uptake of three radiolabelled anti-CEA localising antibodies (A5B7, 1H12 and PK2G) into a human colon tumour xenograft (MaWi) has been examined. For tumour weights greater than 100 mg (109-873 mg) there was a strong positive correlation between absolute uptake and tumour weight with mean uptakes per gram of 9.8 (r = 0.92), 5.0 (r = 0.93) and 5.3 (r = 0.94) for A5B7, 1H12 and PK2G respectively. For tumour weights below 100 mg (17-99 mg) the percentage uptake per gram (specific uptake) increased markedly reaching 80% of the injected dose for A5B7. The above phenomena could be modelled by representing uptake by the surface area of a sphere and tumour weight by its volume. Transformation of this model produced a linear relationship suitable for regression analysis of the experimental data. The slopes of the regression lines for the three antibodies were very close to that predicted by the model suggesting that their uptake into MaWi xenografts is proportional to surface area. The main discrepancy of the actual data was shown by the intercepts which relate to the variation in uptake between different antibodies. This model provides a possible means of correcting for the effect of tumour size when investigating the uptake of antibodies into xenografts.

Citing Articles

Molecular insights into the interplay between adiposity, breast cancer and bone metastasis.

Soni S, Torvund M, Mandal C Clin Exp Metastasis. 2021; 38(2):119-138.

PMID: 33591548 DOI: 10.1007/s10585-021-10076-0.


Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Malik P, Phipps C, Edginton A, Blay J Pharm Res. 2017; 34(12):2579-2595.

PMID: 28924691 DOI: 10.1007/s11095-017-2259-3.


IMAC capture of recombinant protein from unclarified mammalian cell feed streams.

Kinna A, Tolner B, Rota E, Titchener-Hooker N, Nesbeth D, Chester K Biotechnol Bioeng. 2015; 113(1):130-40.

PMID: 26174988 PMC: 4737217. DOI: 10.1002/bit.25705.


Engineering of near IR fluorescent albumin nanoparticles for in vivo detection of colon cancer.

Cohen S, Margel S J Nanobiotechnology. 2012; 10:36.

PMID: 22891637 PMC: 3477047. DOI: 10.1186/1477-3155-10-36.


Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.

Dearling J, Voss S, Dunning P, Snay E, Fahey F, Smith S Nucl Med Biol. 2011; 38(1):29-38.

PMID: 21220127 PMC: 3032412. DOI: 10.1016/j.nucmedbio.2010.07.003.


References
1.
Primus F, Wang R, Goldenberg D, Hansen H . Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res. 1973; 33(11):2977-82. View

2.
Rogers G, Pedley R, Boden J, Harwood P, Bagshawe K . Effect of dose escalation of a monoclonal anti-CEA IgG on tumour localisation and tissue distribution in nude mice xenografted with human colon carcinoma. Cancer Immunol Immunother. 1986; 23(2):107-12. PMC: 11038251. DOI: 10.1007/BF00199815. View

3.
Rogers G, Harwood P, Pedley R, Boden J, Rawlins G, Bagshawe K . Dynamics of monoclonal antibody distribution and prolonged tumour localisation in nude mice bearing a human CEA-producing colon carcinoma xenograft. Tumour Biol. 1986; 6(5):453-63. View

4.
Harwood P, Britton D, Southall P, Boxer G, Rawlins G, Rogers G . Mapping epitope characteristics on carcinoembryonic antigen. Br J Cancer. 1986; 54(1):75-82. PMC: 2001645. DOI: 10.1038/bjc.1986.154. View

5.
Begent R . Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies. Biochim Biophys Acta. 1985; 780(2):151-66. DOI: 10.1016/0304-419x(84)90003-9. View